This campaign has now closed
20% of all new cancers diagnosed will be urological cancer, yet the seriousness of these cancers which represent Kidney, Bladder, Prostate and Testicular has not reached public awareness in the same way as some other cancers. Key to successful treatment is early diagnosis but urological cancers do not have the exposure they warrant. There are 54,000 new cases of urological cancer each year – 10,000 more than breast cancer , prostate cancer being the most common with 35,000 cases diagnosed a year.
Categories
Beneficiaries
Situation
Oxford has made significant contributions both nationally and internationally to cancer research in urology, in particular to cancer of the kidney, bladder and prostate. Research activities in Oxford encompass clinical, translational and basic science programmes on the biology cancers, and Oxford has made significant contributions both nationally and internationally to cancer research in urology. As funds for high calibre projects have previously been hard to come by, UCARE will use this link to Oxford as a centre of excellence; so that the core expertise of researchers dedicated to urology research is maintained. UCARE is funding a scientist who joined a research team at a crucial time to test the new Insulin-like Growth Factor [IGF R1] receptor inhibitory drugs - IGF receptors are vital for the growth and spread of cancer cells. This post is critical to linking the laboratory work to the clinical setting and to move forward with the development of a new treatment for patients with cancers. The results of UCARE funding research into new uses of clinical treatments and technology will have a major impact on the global fight against urological cancers, and help patients worldwide.